A5077226478- Immune cells in cancer
- Histone Deacetylase Inhibitors Research
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Epigenetics and DNA Methylation
- Inflammation biomarkers and pathways
- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- Viral-associated cancers and disorders
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
- Cytokine Signaling Pathways and Interactions
- Pancreatic and Hepatic Oncology Research
- Lymphoma Diagnosis and Treatment
- MicroRNA in disease regulation
- Neutropenia and Cancer Infections
- Ferroptosis and cancer prognosis
- TGF-β signaling in diseases
- Bipolar Disorder and Treatment
- Cancer-related molecular mechanisms research
- Metastasis and carcinoma case studies
- Adenosine and Purinergic Signaling
- Sarcoma Diagnosis and Treatment
- Parvovirus B19 Infection Studies
- Cancer Risks and Factors
Augusta University Health
2013-2024
Augusta University
2008-2022
National Cancer Center of Georgia
2019-2021
Charlie Norwood VA Medical Center
2016-2020
Georgia Regents Medical Center
2013-2015
Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) active as a combination therapy in multiple tumor models.
Type I interferons (IFN-I) have recently emerged as key regulators of tumor response to chemotherapy and immunotherapy. However, IFN-I function in cytotoxic T lymphocytes (CTLs) the microenvironment is largely unknown.
The Fas-FasL effector mechanism plays a key role in cancer immune surveillance by host T cells, but metastatic human colon carcinoma often uses silencing Fas expression as of evasion. molecular under FAS transcriptional is unknown. We performed genome-wide chromatin immunoprecipitation sequencing analysis and identified that the promoter enriched with H3K9me3 cells. level region significantly higher than primary it inversely correlated level. discovered verticillin A selective inhibitor...
Although accumulation of myeloid-derived suppressor cells (MDSC) is a hallmark cancer, the underlying mechanism this within tumor microenvironment remains incompletely understood. We report here that TNFα-RIP1-mediated necroptosis regulates MDSCs. In tumor-bearing mice, pharmacologic inhibition DNMT with DNA methyltransferease inhibitor decitabine (DAC) decreased MDSC and increased activation antigen-specific cytotoxic T lymphocytes. DAC-induced decreases in correlated expression myeloid...
Abstract Inducible nitric oxide synthase (iNOS) generates (NO) in myeloid cells that acts as a defense mechanism to suppress invading microorganisms or neoplastic cells. In tumor-bearing mice, elevated iNOS expression is hallmark of myeloid-derived suppressor (MDSC). MDSCs use NO nitrate both the T-cell receptor and STAT1, thus inhibiting activation antitumor immune response. The molecular mechanisms underlying regulation tumor-induced are unknown. We report here deficiency IRF8 results...
The study goal was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-C-C chemokine receptor 4 (anti-CCR4) mAb targeting effector regulatory T cells (eTreg), in combination with checkpoint inhibitors durvalumab or tremelimumab.This a multicenter, phase I, dose escalation study, followed by disease-specific cohort expansion (NCT02301130). Mogamulizumab proceeded concurrent tremelimumab patients advanced solid tumors. Cohort occurred mogamulizumab 1...
4015 Background: The indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that exploited by tumors to prevent and evade anti-tumor immunity. Inhibitors of the IDO pathway, such as indoximod, are an increasingly validated class potential cancer therapeutics. combination gemcitabine (G) nab-paclitaxel (N) current SOC for metastatic pancreas (MPC). Pre-clinical models have demonstrated synergy between indoximod chemotherapy. Methods: Single arm study with (1200mg BID...
Abstract Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with checkpoint inhibitor nivolumab patients locally advanced or metastatic solid tumors. Patients Methods: This a multicenter, dose-finding (phase I), dose expansion II) (NCT02705105) There were no dose-limiting toxicities phase I mogamulizumab 1 mg/kg every week for cycle...
// Amy V. Paschall 1, 2, 3 , Dafeng Yang Chunwan Lu Priscilla S. Redd Jeong-Hyeon Choi 2 Christopher M. Heaton Jeffrey R. Lee Asha Nayak-Kapoor Kebin Liu 1 Department of Biochemistry and Molecular Biology, Medical College Georgia, Augusta University, Augusta, GA 30912, USA Georgia Cancer Center, Charlie Norwood VA 30904, Correspondence to: Liu, email: Kliu@augusta.edu Keywords: CD133, CD24, colon cancer stem cells, 5-Fluorouracil Received: January 14, 2016 Accepted: September 12, Published:...
A hallmark of human colorectal cancer is lost expression FAS, the death receptor for FASL cytotoxic T lymphocytes (CTLs). However, it unknown whether restoring FAS alone sufficient to suppress csolorectal-cancer development. The promoter hypermethylated and inversely correlated with mRNA level in carcinomas. Analysis single-cell RNA-Seq datasets revealed that highly expressed epithelial cells immune but down-regulated colon-tumor colorectal-cancer patients. Codon usage-optimized mouse cDNA...
BACKGROUND. Plasmablastic lymphoma (PBL) is a rare form of non-Hodgkin that was once believed to occur primarily in the oral cavity human immunodeficiency virus-positive individuals. Numerous extraoral sites have also been reported date. To authors' knowledge, however, only 3 reports literature describe its cytologic features. In current study, findings 5 additional patients are reported, whom had concomitant second malignancies. The goal study define cytomorphologic features may help...
Abstract The chemotherapeutic agent 5-fluorouracil (5-FU) is the standard therapy for patients with advanced colorectal cancer (CRC). 5-FU not only targets tumor cells apoptosis but also induces in myeloid cells, leading to myelosuppression, which has long been thought as a side effect of therapy. Myeloid-derived suppressive (MDSCs) are heterogeneous population immature that exhibit potent activity inhibit T and NK cell function. Recent studies have found suppresses MDSCs mouse models....
Abstract The Fas-FasL effector mechanism plays a key role in cancer immune surveillance by host T cells, but metastatic human colorectal carcinoma (CRC) often uses silencing of Fas expression as evasion. molecular FAS transcriptional CRC is unknown. We performed genome-wide ChIP-Sequencing analysis and determined that the level H3K9me3 promoter region significantly higher than primary inversely correlated with expression. discovered verticillin A selective inhibitor histone...
549 Background: Vitamin D deficiency is associated with increased colorectal cancer (CRC) risk and decreased survival. The purpose of this study was to determine the effect adjuvant treatment on vitamin status in CRC. Methods: 102 patients at GCC Stage I-III CRC were selected between 2009 -2011. A retrospective analyses baseline these made if level predicts Those who have received neoadjuvant excluded. Only had a drawn included. sufficiency defined as serum 30ng/ml or greater, insufficiency...
Abstract Myeloid-derived suppressive cells (MDSCs) are potent immune that accumulate with tumor progression. Compelling data from mouse models and human cancer patients have shown tumor-induced inflammation induces MDSC differentiation. However, the mechanisms underlying persistence is unknown. Here, we made use of orthotopic mammary colon carcinoma demonstrated MDSCs exhibit significantly decreased spontaneous apoptosis in vivo, as well sensitivity to FasL-induced vitro, compared myeloid...
<div>Abstract<p>Inducible nitric oxide synthase (iNOS) generates (NO) in myeloid cells that acts as a defense mechanism to suppress invading microorganisms or neoplastic cells. In tumor-bearing mice, elevated iNOS expression is hallmark of myeloid-derived suppressor (MDSC). MDSCs use NO nitrate both the T-cell receptor and STAT1, thus inhibiting activation antitumor immune response. The molecular mechanisms underlying regulation tumor-induced are unknown. We report here...
<div>Abstract<p>Although accumulation of myeloid-derived suppressor cells (MDSC) is a hallmark cancer, the underlying mechanism this within tumor microenvironment remains incompletely understood. We report here that TNFα–RIP1–mediated necroptosis regulates MDSCs. In tumor-bearing mice, pharmacologic inhibition DNMT with DNA methyltransferease inhibitor decitabine (DAC) decreased MDSC and increased activation antigen-specific cytotoxic T lymphocytes. DAC-induced decreases in...
<div>Abstract<p>Although accumulation of myeloid-derived suppressor cells (MDSC) is a hallmark cancer, the underlying mechanism this within tumor microenvironment remains incompletely understood. We report here that TNFα–RIP1–mediated necroptosis regulates MDSCs. In tumor-bearing mice, pharmacologic inhibition DNMT with DNA methyltransferease inhibitor decitabine (DAC) decreased MDSC and increased activation antigen-specific cytotoxic T lymphocytes. DAC-induced decreases in...
<p>Supplemental Figures 1-7. Figure S1. IRF8 expression profiles in subsets of immune cells spleens tumor-bearing mice. S2. peripheral blood S3. DNA methylation and MDSC accumulation S4. Inhibition activates antigen-specific CTLs S5. Neutralization TNFα increases tumor growth accumulation. S6. RIP1 RIP3 are expressed MDSCs. S7. IL6 level human colon carcinoma melanoma. Table Colorectal cancer patient data. Colon data.</p>
<p>Supplemental Figures 1-7. Figure S1. IRF8 expression profiles in subsets of immune cells spleens tumor-bearing mice. S2. peripheral blood S3. DNA methylation and MDSC accumulation S4. Inhibition activates antigen-specific CTLs S5. Neutralization TNFα increases tumor growth accumulation. S6. RIP1 RIP3 are expressed MDSCs. S7. IL6 level human colon carcinoma melanoma. Table Colorectal cancer patient data. Colon data.</p>